Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Janux Therapeutics (NASDAQ:JANX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $37.58, despite some recent price target reductions. The company's stock opened at $17.52 with a market capitalization of $1.07 billion, and its latest quarterly results missed analyst expectations for both EPS and revenue. Institutional investors hold a significant 75.39% stake in Janux Therapeutics, a clinical-stage biotechnology company focused on immuno-oncology therapies.
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX
Dimensional Fund Advisors LP significantly reduced its stake in Janux Therapeutics, Inc. by 56.9% in the first quarter, now holding 96,630 shares valued at approximately $1.34 million. Despite Janux Therapeutics missing consensus estimates for its recent quarterly earnings and revenue, institutional investors collectively own 75.39% of the company's stock. Analysts currently rate JANX as a "Moderate Buy" with a consensus price target of $37.58, which is substantially higher than its recent trading price of $16.12.
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund
Point72 Asset Management and its related entities, including Point72 Capital Advisors, Inc. and Steven A. Cohen, have reported a beneficial ownership of 1,993,837 shares of Janux Therapeutics (JANX) common stock, representing 3.3% of the outstanding class as of June 30, 2026. This stake is held through investment funds managed by Point72, with shared voting and dispositive power among the reporting persons. The filing, a Schedule 13G/A, indicates that the ownership is below 5% and is for passive investment purposes.
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management
Janus Henderson Group Ltd. has reported beneficial ownership of 172,229 shares of Janux Therapeutics, Inc. common stock, which represents a 0.3% stake in the company. These shares are held across various client accounts managed by Janus Henderson's investment adviser subsidiaries, and the group exercises shared voting and dispositive power over them. The filing clarifies that the dividends and sale proceeds from these shares accrue to the Managed Portfolios, not Janus Henderson directly, and no single Managed Portfolio holds more than five percent of Janux Therapeutics' common stock.
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35
Stifel has reiterated its Buy rating for Janux Therapeutics (JANX.US) and maintained its target price at $35. This indicates a continued positive outlook from the investment firm regarding the company's stock performance.
The Janux Therapeutics, Inc. (NASDAQ:JANX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Janux Therapeutics reported its second-quarter results, showing significant revenue growth from collaborations and a substantial cash reserve. Analysts have updated their forecasts, maintaining a "buy" consensus with a new average price target of US$47.90, indicating a potential 30% upside from the current share price. The company's financial health appears strong, supported by its cash position and ongoing R&D investments.
Equities Analysts Set Expectations for JANX Q3 Earnings
HC Wainwright has revised its Q3 2026 EPS estimate for Janux Therapeutics (NASDAQ:JANX) to a loss of $0.45 per share, an improvement from its previous estimate. Despite this, Janux Therapeutics recently reported quarterly earnings that fell short of expectations, with an EPS loss of $0.35 against an estimated $0.25 loss and lower-than-expected revenue. The company maintains a "Moderate Buy" analyst rating with an average price target of $37.58, while institutional investors hold a significant 75.39% stake in the stock.
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings
HC Wainwright has lowered its FY2030 earnings per share (EPS) estimate for Janux Therapeutics (NASDAQ:JANX) to $0.97, down from $1.06, while the consensus remains a loss of $1.70 per share. This adjustment follows Janux's recent quarterly earnings report, where the company missed analyst expectations with a loss of $0.35 per share and revenue of $10.27 million against an anticipated $19.07 million. Despite the lowered forecast and recent price target reductions from other analysts, Janux Therapeutics still holds a "Moderate Buy" consensus rating with an average target price significantly higher than its current share price.
Janux Therapeutics Inc (JANX) Stock News Today
This article provides an overview of Janux Therapeutics Inc (JANX) stock information, including its current trading price, market capitalization, and a note that more news is coming soon. It also lists various financial and analytical tools available on the platform for users interested in the company.
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile
Janux Therapeutics (JANX) saw its stock rise by 7.1% after announcing a narrower net loss for the second quarter and first half of 2026. The company reported a net loss of US$21.97 million, or US$0.35 per share, in Q2 2026, an improvement from US$33.86 million, or US$0.55 per share, a year prior. While this indicates better cost control, the article notes that funding needs and dilution risk remain key concerns for investors due to the company's high valuation multiples and ongoing unprofitability.
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating
RBC Capital Markets has increased its price target for Janux Therapeutics (JANX) to $34 from $30, while reiterating an Outperform rating on the stock. This adjustment reflects RBC's continued positive outlook on the company.
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results
Janux Therapeutics, Inc. (NASDAQ:JANX) missed its latest quarterly earnings expectations, with revenues significantly lower than forecasts and per-share losses exceeding predictions. As a result, analysts have reduced their revenue estimates for 2026 and increased their loss per share forecasts, though the consensus price target remains largely unchanged. Despite these adjustments, the company's projected revenue growth is still expected to be in line with the broader industry.
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating
RBC Capital has increased its price target for Janux Therapeutics (JANX) to $34 from $30, while reiterating an Outperform rating. This adjustment comes after Janux Therapeutics reported its Q2 revenue of $10.3 million, falling short of FactSet's estimate of $19.1 million. The company is a clinical-stage biopharmaceutical firm focusing on tumor-activated immunotherapies for cancer.
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results
Analysts have reduced their revenue and increased their loss per share forecasts for Janux Therapeutics (NASDAQ:JANX) after the company missed earnings in its latest quarterly results. Despite the lowered expectations, the consensus price target remains largely unchanged, suggesting that the intrinsic value of the business is perceived to be stable. The company's revenue growth is still expected to align with the industry average, but investors are advised to focus on the long-term trajectory.
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating for Janux Therapeutics Inc (JANX) with a price target of $22.00. While other analysts like William Blair also issued a Buy rating, Barclays maintained a Sell rating. The company recently reported a quarterly revenue of $3.73 million and a GAAP net loss of $24.36 million, and corporate insider sentiment is negative due to increased insider selling.
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside
Janux Therapeutics, Inc.'s average 12-month price target has been slightly reduced by analysts from $33.56 to $33.25, with a range of $14 to $60 per share. Despite the cut, the new target still implies a significant 107% potential upside based on the Aug. 6 closing price. The consensus rating for the stock remains a "Buy" among 18 covering analysts.
Janux Therapeutics (NASDAQ: JANX) posts Q2 loss on collaboration revenue
Janux Therapeutics reported a Q2 2026 net loss of $22.0 million, narrowing from $33.9 million a year prior, driven by $10.3 million in collaboration revenue from its Bristol-Myers Squibb agreement. For the first half of 2026, the company recorded $14.0 million in collaboration revenue and a net loss of $46.3 million. Janux maintains a strong financial position with over $1 billion in total assets as of June 30, 2026, and expects existing capital to fund operations for at least the next 12 months.
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported its financial results for the second quarter of 2026, highlighting continued progress across its clinical programs, including JANX007, JANX014, and JANX011. The company maintains a strong financial position with $970.9 million in cash and investments and anticipates several key clinical milestones in late 2026 and early 2027. Net loss for the quarter was $22.0 million, an improvement from $33.9 million in the comparable period of 2025.
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) reported a Q2 loss of $0.35 per share, missing the Zacks Consensus Estimate of a $0.26 loss, though it improved from a $0.55 loss a year ago. The company also missed revenue estimates, posting $10.27 million against an expectation of zero revenues a year prior. Despite this, Janux Therapeutics shares have risen 15.9% year-to-date, outperforming the S&P 500, and currently hold a Zacks Rank #3 (Hold).
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M
Janux Therapeutics, Inc. (JANX) reported its Q2 revenue at $10.3 million, falling short of the FactSet estimate of $19.1 million. The article also mentions other recent news concerning the company, including a report of earnings results for the second quarter and six months ended June 30, 2026, and its removal from several Russell Growth Benchmarks.
BRIEF-Janux Therapeutics Q2 Basic EPS USD -0.35
Janux Therapeutics reported a Q2 basic EPS of USD -0.35. The article, sourced from Reuters, provides this brief financial update.
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported its second-quarter 2026 financial results, highlighting continued progress across its clinical portfolio. The company maintained a strong financial position with $970.9 million in cash, cash equivalents, and short-term investments, supporting the advancement of multiple clinical programs including JANX007, JANX014, and JANX011. Janux anticipates announcing initial clinical data for JANX011 and initiating clinical development for JANX013 in the second half of 2026, with further data for JANX007 expected in the first half of 2027.
Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Gamble with 142% Potential Upside
Janux Therapeutics (JANX) is a clinical-stage biopharmaceutical company focusing on immunotherapies for cancer, showing a potential upside of over 142% according to analysts. Despite negative financial metrics typical of early-stage biotech firms, Janux benefits from strategic collaborations with major pharmaceutical companies and a robust clinical pipeline. The company presents a high-risk, high-reward opportunity for investors interested in innovative cancer therapies.
Form 4 Janux Therapeutics Inc For: 31 July By Investing.com
This article reports on the filing of a Form 4 for Janux Therapeutics Inc. as of July 31st. It indicates that the filing is a standard disclosure related to insider trading or changes in ownership, as typically required by the SEC. The brief entry notes the company's stock symbol JANX and a slight dip in its price.
Form 4 Janux Therapeutics Inc For: 31 July By Investing.com
This article announces the filing of a Form 4 for Janux Therapeutics Inc. for the period ending July 31. It provides no further details beyond this announcement and includes general market data and related news. The Form 4 filing is a mandatory SEC document reporting changes in beneficial ownership of a company's securities by insiders.
Form 4 Janux Therapeutics Inc For: 31 July By Investing.com
This article announces the filing of Form 4 by Janux Therapeutics Inc. for July 31. It includes various market data such as indices, commodities, and shares, along with trending stocks and popular news articles from Investing.com. The piece focuses on financial updates and general market movements.
Janux Therapeutics Inc (JANX) Institutional Confidence
Janux Therapeutics Inc (JANX) has an institutional shareholding score of 10.00, ranking 1st in its industry. The institutional shareholding proportion increased by 0.64% quarter-over-quarter, reaching 110.21%. Steven Cohen is the largest institutional shareholder, though his holdings decreased by 62.25%.
Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis
Janux Therapeutics Inc (JANX) currently holds a financial score of 7.85, ranking 76th out of 384 companies in the Biotechnology & Medical Research industry. The company's financial status is deemed stable, while its operating efficiency is considered average. Key financial metrics such as total revenue, operating profit, and cash flow from operating activities have not yet been disclosed by the company.
Janux Therapeutics Inc (JANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Janux Therapeutics Inc (JANX), detailing its price momentum score of 3.51 within the Biotechnology & Medical Research industry. It identifies current support at $14.46 and resistance at $16.80, suggesting suitability for range-bound swing trading. The analysis also includes specific technical indicator readings (MACD, RSI, KDJ, etc.) and moving average data, concluding with a "Neutral" signal based on these metrics.
Understanding Momentum Shifts in (JANX)
An analysis of Janux Therapeutics Inc. (NASDAQ: JANX) indicates weak sentiment across all time horizons, supporting a short bias. The article identifies a mid-channel oscillation pattern and highlights an exceptional 99.0:1 risk-reward short setup targeting a 29.8% downside. AI-generated trading strategies are provided for position trading (long), momentum breakout, and risk hedging (short).
Janux Therapeutics, Inc. Revenue Breakdown – NASDAQ:JANX
Janux Therapeutics, Inc. (NASDAQ:JANX) generated $10.00 million USD in revenue last year, primarily from its Novel Immunotherapies segment, which also contributed $10.00 million USD in revenue. The United States was its largest geographical contributor, also accounting for $10.00 million USD in revenue in the previous fiscal year. This marks a slight decrease from the $10.59 million USD generated in the prior year across both the segment and country.
Janux Therapeutics Inc (JANX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Janux Therapeutics Inc (JANX), noting its current valuation score of 7.63, which ranks it 208 out of 384 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -8.12, comparing it to recent highs and lows. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
BlackRock (NYSE: BLK) discloses 6.7% beneficial stake in Janux Therapeutics (JANX)
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.7% beneficial ownership in Janux Therapeutics, Inc., amounting to 4,098,457 shares as of June 30, 2026. The filing indicates BlackRock holds sole voting power over 4,024,396 shares and sole dispositive power over all 4,098,457 shares. While various clients benefit from these holdings, no single client owns more than five percent of Janux's outstanding common shares.
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides information regarding Janux Therapeutics Inc (JANX) stock, focusing on its dividend and stock split history. It states that the company has not distributed any dividends over the past five years. Key financial data like market cap and current stock price are also displayed, but no specific dividend or split events are listed.
JANX|Janux Therapeutics Inc|Price:15.635|Chg%:+0.305
Janux Therapeutics Inc (JANX) has a TradingKey Stock Score of 6.70/10, indicating relatively healthy fundamentals and high growth potential, though its valuation is only considered fair. The company specializes in developing tumor-activated immunotherapies for cancer, with significant revenue and profit growth. Analysts have a positive outlook, with a significant upside space to target price, despite recent institutional selling.
Janux Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance
Janux Therapeutics Inc. (JANX) is a clinical-stage biopharmaceutical company focused on developing tumor-activated immunotherapies for cancer using its TRACTr and TRACIr platforms. The company's clinical candidates, JANX007 and JANX008, target prostate cancer and various solid tumors respectively. The article provides an overview of the company's profile, including ticker symbol, IPO date, key executives, and institutional shareholdings.
Janux Therapeutics Inc (JANX) Income Statement
This article presents the quarterly and annual income statements for Janux Therapeutics Inc. (JANX), detailing revenue, operating expenses, research and development costs, and net income figures. It provides insights into the company's financial performance and efficiency over various fiscal periods, alongside a FAQ section explaining how to interpret the income statement data.
Janux Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Barrett Ronald W
This article is a statement of changes in beneficial ownership of securities for Director Ronald W. Barrett of Janux Therapeutics. It is identified as a Form 4 filing, which indicates a required disclosure of stock transactions by company insiders. The full content is described as a "Document" which suggests it contains detailed financial transaction data.
Avoiding Lag: Real-Time Signals in (JANX) Movement
This article provides a real-time stock analysis for Janux Therapeutics Inc. (NASDAQ: JANX), indicating near-term weak sentiment but mid-term strength within a broader long-term weak bias. It highlights specific resistance and support levels, along with three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each with entry zones, targets, and stop losses. The analysis also emphasizes the exceptional risk-reward short setup targeting significant downside.
Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings
Janux Therapeutics President and CEO David Alan Campbell exercised stock options to acquire 7,000 shares of common stock at an exercise price of $4.21 per share. This transaction, which occurred on July 8, 2026, increased his direct holdings to 388,582 common shares, while he still retains 697,550 immediately exercisable stock options. The filing is considered a routine compensation-related equity exercise rather than a change in strategic ownership.
Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth Indexes - What's Changed
Janux Therapeutics (JANX) shares rose 13.6% despite its recent removal from several Russell growth benchmarks, including the Russell 3000 and 2000. The article suggests this removal is a technical detail affecting liquidity and investor base rather than fundamental business changes. The company's investment narrative remains tied to its TRACTr platform and Bristol Myers Squibb partnership, with upcoming clinical trial catalysts for JANX007 and JANX014.
Avoiding Lag: Real-Time Signals in (JANX) Movement
Janux Therapeutics Inc. (NASDAQ: JANX) is testing resistance, with strong near and mid-term sentiment but a weak long-term outlook. AI models have generated distinct trading strategies, including a long position, a momentum breakout, and a short hedging strategy, highlighting an exceptional risk-reward short setup. The analysis provides multi-timeframe signal insights and real-time trading signals for investors.
Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth Indexes - What's Changed
Janux Therapeutics (JANX) saw a 13.6% increase in its stock price despite being removed from several Russell growth indexes in late June 2026. This removal is considered a technical flow issue rather than a change in fundamental business aspects for the company. The article suggests that investors should focus on Janux's TRACTr platform, its partnership with Bristol Myers Squibb, and clinical trial progress, while also considering liquidity and potential volatility.
Price to sales forward of Janux Therapeutics, Inc. – NASDAQ:JANX
The article focuses on the "Price to sales forward" metric for Janux Therapeutics, Inc. (NASDAQ: JANX). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, technical analysis, and market data. The content is primarily a listing of navigation and service offerings from the TradingView platform.
Price to earnings forward of Janux Therapeutics, Inc. – NASDAQ:JANX
This article provides financial information for Janux Therapeutics, Inc. (NASDAQ: JANX) focusing on its price to earnings forward metric. The content highlights a specific period, its value, and the percentage change. It appears to be an excerpt from a financial data platform like TradingView.
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark
Janux Therapeutics, Inc. (JANX) has been removed from the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth, Russell 3000E Growth, and Russell Small Cap Comp Growth benchmarks. This news follows a series of recent updates including leadership changes, analyst price target adjustments, Q1 2026 earnings results, and the discontinuation of a cancer drug candidate, JANX008. The company is a clinical-stage biopharmaceutical firm developing tumor-activated immunotherapies for cancer.
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark
Janux Therapeutics, Inc. (NasdaqGM: JANX) has been removed from the Russell 3000 Growth Benchmark, as well as the Russell 2500, Russell 2000, and Russell 3000E Growth Benchmarks. This news follows several other recent updates for the company, including leadership changes, adjusted price targets from analysts, and reports on its Q1 revenue and clinical trial developments.
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark
Janux Therapeutics, Inc. (NasdaqGM:JANX) has been removed from the Russell 2000 Growth Benchmark as of June 29, 2026. The biopharmaceutical company is currently developing tumor-activated immunotherapies for cancer, utilizing its TRACTr, TRACIr, and ARM bispecific platforms. This news follows several recent updates including earnings results, analyst rating adjustments, and the discontinuation of development for one of its cancer drug candidates.
5 Most Promising Cancer Stocks According to Wall Street Analysts
This article identifies five promising cancer stocks according to Wall Street analysts, focusing on companies with significant price target upsides and pipeline developments. It highlights Janux Therapeutics, Inc. (NASDAQ:JANX) as one such company, detailing analyst ratings, its TRACTr platform, and recent leadership changes while emphasizing that its development strategy remains unaffected. The full article, which lists 10 companies, is available on the Insider Monkey website.
Discipline and Rules-Based Execution in JANX Response
Stock Traders Daily's Quantitative Research Desk has analyzed Janux Therapeutics Inc. (NASDAQ: JANX), identifying strong near and mid-term sentiment but a weak long-term outlook. The analysis highlights an exceptional risk-reward short setup targeting a 29.6% downside with minimal risk. Three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—are provided for different risk profiles.
